查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1971523

非银抗菌敷料市场 - 全球产业规模、份额、趋势、机会、预测、区域及竞争格局（2021-2031）

Non-Silver Antimicrobial Dressings Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

全球非银抗菌敷料市场预计将从 2025 年的 4.9455 亿美元成长到 2031 年的 6.2975 亿美元，复合年增长率为 4.11%。

这些先进的创伤护理方案利用碘、蜂蜜、聚六亚甲基双胍 (PHMB) 和氯己定等替代性消毒剂来控制感染和微生物附着量，而无需依赖银。推动这一增长的主要因素是慢性病（尤其是糖尿病和血管疾病）在全球范围内的日益流行，这些疾病导致难治性溃疡的发生率增加，而这些溃疡需要有效的感染控制。此外，临床上对银的抗药性和细胞毒性的担忧也促使人们采用这些非银替代品。例如，国际糖尿病联盟 (IDF) 报告称，到 2024 年，全球将有约 5.89 亿成年人患有糖尿病，这是一个庞大的患者群体，需要可靠的抗菌干预措施。

市场概览
预测期 2027-2031
市场规模：2025年 4.9455亿美元
市场规模：2031年 6.2975亿美元
复合年增长率：2026-2031年 4.11%
成长最快的细分市场
最大的市场 北美洲

儘管市场需求强劲，但由于严格的法规结构和不稳定的报销环境，该市场面临许多障碍。製造商必须应对复杂的核准流程，该流程要求提供大量的临床证据，以证明这些替代疗法符合既定标准的安全性和有效性。此外，公共医疗系统的预算限制往往限制了这些先进治疗方法的应用，迫使医疗服务提供者依赖成本较低的传统敷料。这种经济障碍阻碍了成本敏感地区的推广，从而限制了全球非银抗菌敷料市场的整体成长潜力。

市场驱动因素

由于老化与慢性伤口风险之间存在密切联繫，全球老年人口的快速增长是推动非银抗菌敷料普及的主要动力。随着老龄化，生理机能会逐渐衰退，例如皮肤弹性下降和免疫反应减弱，这显着增加了褥疮和静脉性腿部溃疡等难治性疾病的风险。这些慢性问题通常需要长期感染控制，而医用蜂蜜和聚羟基丁酸酯（PHMB）等替代製剂往往比银基产品更受欢迎，以避免细胞毒性和抗药性问题。联合国人口基金（UNFPA）2024年6月发布的《老化》报告也印证了这项人口结构变化，报告指出，到2024年，全球65岁及以上人口的比例将达到10.3%，这意味着需要持续、先进的创伤护理的患者群体正在不断扩大。

同时，手术部位感染（SSI）的日益增加以及对强有力的术后感染控制的需求，正显着推动市场成长。医疗机构对抗菌敷料的需求不断增长，这些敷料既能降低外科性创伤的微生物附着量，又能避免传统银基疗法带来的细菌抗药性风险。根据美国疾病管制与预防中心（CDC）于2024年11月发布的《2023年国家和州医疗保健相关感染进展报告》，全子宫切除术后SSI的发生率同比增长8%，凸显了手术环境中感染预防面临的持续挑战。这种临床上的紧迫性正在推动製造商的商业性成功；例如，康维特集团在2024年报告称，其先进创伤护理业务在2023财年实现了9.5%的有机收入增长，这主要得益于其抗菌产品系列的强劲表现。

市场挑战

严格的监管要求、不一致的报销政策以及公共医疗体系的预算限制，严重阻碍了非银抗菌敷料市场的发展。这些经济和监管障碍导致非银抗菌敷料的临床疗效与商业性可行性之间存在差距。儘管这些替代敷料具有细胞毒性较低等优势，但由于复杂的报销机制未能充分反映其高于标准治疗产品的初始成本，因此其推广应用往往受到阻碍。因此，预算固定的医疗机构通常难以证明这些先进解决方案的高价合理，除非能够获得全额报销，否则只能依赖疗效较差但价格更低的替代方案。

在对成本高度敏感的市场中，资金筹措差异直接影响筹资策略，这种财务压力尤其严峻。根据欧洲伤口管理协会 (EWMA) 2024 年的报告，一些欧洲国家对先进创伤护理产品的报销方案通常仅覆盖总成本的 60% 至 90%，剩余的费用则由患者或医疗机构承担。因此，儘管临床上对非银基疗法的需求十分明确，但由于缺乏全面的报销方案，采购部门不得不选择成本较低的传统敷料，从而限制了市场扩张的潜力。

市场趋势

重塑市场格局的关键趋势之一是转型为生物相容性和非细胞毒性材料。医疗保健专业人员越来越重视那些能够促进伤口癒合且避免长期接触银所带来的细胞毒性风险的解决方案。临床医生不再仅仅依赖传统的杀菌剂，而是转向使用生物支架和先进基质，这些材料能够积极促进组织再生并控制微生物附着量。胎盘细胞外基质技术需求的增长清晰地体现了这一转变，该技术为复杂伤口护理提供了非细胞毒性的选择。例如，康维特集团在其2025年2月发布的截至2024年12月31日的年度财务报告中指出，其InnovaMatrix平台的收入增长了34%，达到9900万美元，这印证了临床实践正迅速转向这些生物相容性、非银基的治疗方案。

同时，门诊和居家照护专用敷料的推广应用正推动显着的商业活动。这主要得益于旨在促进患者早期出院和在院外管理慢性疾病的策略性医疗保健政策。为此，製造商正在开发高度便携、持久耐用且操作简便的敷料系统，供看护者和患者在非临床环境中使用。随着门诊场所逐渐成为初级医疗保健中心，针对适用于门诊环境的设计，例如高吸收性泡沫敷料和一次性负压敷料系统，正带来显着的收入成长。根据史密斯医疗（Smith & Nephew）于2025年2月发布的“2024财年第四季度及全年业绩报告”，该公司高级伤口管理部门第四季度核心收入增长12.2%，创下全年最高业绩。这主要得益于适用于长期照护环境的技术的稳步普及。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：非银抗菌敷料的全球市场展望

  • 市场规模及预测
    • 按金额
  • 市占率及预测
    • 按地区
    • 按公司（2025 年）
  • 市场地图

第六章：北美非银抗菌敷料市场展望

  • 市场规模及预测
  • 市占率及预测
  • 北美洲：国别分析
    • 我们
    • 加拿大
    • 墨西哥

第七章：欧洲非银抗菌敷料市场展望

  • 市场规模及预测
  • 市占率及预测
  • 欧洲：国别分析
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙

第八章：亚太地区非银抗菌敷料市场展望

  • 市场规模及预测
  • 市占率及预测
  • 亚太地区：国别分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲

第九章：中东和非洲非银抗菌敷料市场展望

  • 市场规模及预测
  • 市占率及预测
  • 中东与非洲：国别分析
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非

第十章：南美洲非银抗菌敷料市场展望

  • 市场规模及预测
  • 市占率及预测
  • 南美洲：国别分析
    • 巴西
    • 哥伦比亚
    • 阿根廷

第十一章 市场动态

  • 促进因素
  • 任务

第十二章 市场趋势与发展

  • 併购
  • 产品发布
  • 近期趋势

第十三章：全球非银抗菌敷料市场：SWOT分析

第十四章：波特五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的议价能力
  • 顾客权力
  • 替代品的威胁

第十五章 竞争格局

  • Cardinal Health, Inc.
  • Essity AB
  • Winner Medical Co., Ltd.
  • Medline Industries, LP
  • DeRoyal Industries, Inc.
  • Smith & Nephew Plc
  • Advanced Medical Solutions Group plc
  • Organogenesis Inc.
  • Convatec Group Plc
  • Kane Biotech Inc.

第十六章 策略建议

第十七章：关于研究公司及免责声明

简介目录
Product Code: 27144

The Global Non-Silver Antimicrobial Dressings Market is projected to expand from USD 494.55 Million in 2025 to USD 629.75 Million by 2031, reflecting a CAGR of 4.11%. These advanced wound care solutions utilize alternative biocidal agents such as iodine, honey, polyhexamethylene biguanide (PHMB), or chlorhexidine to manage infection and bioburden without relying on silver. A major catalyst for this growth is the increasing global prevalence of chronic diseases, particularly diabetes and vascular conditions, which heighten the incidence of hard-to-heal ulcers requiring effective infection control. Additionally, clinical concerns regarding silver resistance and cytotoxicity are encouraging the adoption of these non-silver alternatives. Highlighting the scale of the issue, the International Diabetes Federation reported that approximately 589 million adults were living with diabetes globally in 2024, representing a massive patient population in need of reliable antimicrobial interventions.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 494.55 Million
Market Size 2031USD 629.75 Million
CAGR 2026-20314.11%
Fastest Growing Segment
Largest MarketNorth America

Despite this strong demand, the market faces significant hurdles due to stringent regulatory frameworks and inconsistent reimbursement landscapes. Manufacturers are required to navigate complex approval processes that demand substantial clinical evidence to prove the safety and efficacy of these alternative agents against established standards. Furthermore, budgetary limitations within public healthcare systems frequently restrict coverage for these advanced therapies, compelling providers to rely on lower-cost traditional dressings. This economic barrier hampers widespread adoption in cost-sensitive regions, thereby limiting the overall expansion potential of the Global Non-Silver Antimicrobial Dressings Market.

Market Driver

The rapid expansion of the global geriatric population acts as a primary force propelling the adoption of non-silver antimicrobial dressings, given the intrinsic link between aging and susceptibility to chronic wounds. As people age, physiological deterioration, including reduced skin elasticity and compromised immune responses, significantly elevates the risk of difficult-to-treat conditions such as pressure injuries and venous leg ulcers. These chronic issues often necessitate prolonged infection management, where alternative agents like medical honey or PHMB are favored over silver to circumvent potential issues with cytotoxicity and resistance. Underscoring this demographic shift, the United Nations Population Fund's June 2024 'Ageing' report noted that the global share of individuals aged 65 and older rose to 10.3% in 2024, confirming an expanding patient pool that requires sustained advanced wound care.

In parallel, the increasing prevalence of surgical site infections (SSIs) and the imperative for robust post-operative infection control are substantially fueling market growth. Healthcare institutions are actively seeking antimicrobial dressings capable of reducing bioburden in surgical wounds while avoiding the bacterial resistance risks associated with traditional silver therapies. According to the Centers for Disease Control and Prevention's '2023 National and State Healthcare-Associated Infections Progress Report' released in November 2024, SSIs following abdominal hysterectomies rose by 8% over the prior year, emphasizing the ongoing struggle with infection prevention in surgical environments. This clinical urgency is driving commercial success for manufacturers; for instance, Convatec Group Plc reported in 2024 that its Advanced Wound Care business achieved 9.5% organic revenue growth for fiscal year 2023, largely attributed to the strong performance of its antimicrobial portfolios.

Market Challenge

The market is significantly impeded by a combination of strict regulatory requirements, inconsistent reimbursement policies, and budgetary constraints within public healthcare systems. These economic and regulatory barriers create a disconnect between the clinical efficacy of non-silver antimicrobial dressings and their commercial viability. Although these alternatives offer benefits such as reduced cytotoxicity, their uptake is often hindered by complex reimbursement structures that do not adequately factor in their higher upfront costs compared to standard-of-care products. Consequently, healthcare providers operating under fixed budgets frequently find it difficult to justify the premium pricing of these advanced solutions without guaranteed full coverage, leading them to rely on less effective, cheaper options.

This financial pressure is particularly severe in cost-sensitive markets where gaps in funding directly influence procurement strategies. According to the European Wound Management Association in 2024, reimbursement mechanisms for advanced wound care products in select European countries typically covered only 60% to 90% of the total cost, forcing patients or institutions to absorb the remaining financial burden. As a result, despite the clear clinical demand for non-silver therapies, the absence of comprehensive reimbursement forces procurement departments to default to lower-cost traditional dressings, thereby restricting the market's potential for expansion.

Market Trends

A significant trend reshaping the market is the shift toward biocompatible and non-cytotoxic material profiles, as healthcare professionals increasingly prioritize solutions that facilitate healing without the cellular toxicity risks linked to prolonged silver exposure. Clinicians are moving toward biologic scaffolds and advanced matrices that manage bioburden while actively promoting tissue regeneration, rather than depending solely on traditional biocidal agents. This evolution is highlighted by the rising demand for placental extracellular matrix technologies, which provide a non-cytotoxic option for treating complex wounds. For example, Convatec Group reported in February 2025 within its 'Annual Results for the year ended 31 December 2024' that revenue for its InnovaMatrix platform surged by 34% to $99 million, underscoring the rapid clinical transition toward these biocompatible, non-silver therapeutic options.

Concurrently, the expansion of specialized dressings for ambulatory and home care settings is driving substantial commercial activity, motivated by strategic healthcare initiatives to discharge patients earlier and manage chronic conditions outside of hospitals. Manufacturers are responding by engineering portable, long-wear, and intuitive dressing systems tailored for use by caregivers or patients in non-clinical environments. This emphasis on ambulatory-friendly designs, such as high-absorbency foams and single-use negative pressure systems, is generating significant revenue growth as these settings become primary care locations. According to Smith+Nephew's 'Fourth Quarter and Full Year 2024 Results' published in February 2025, their Advanced Wound Management unit achieved 12.2% underlying revenue growth in the fourth quarter-its strongest yearly performance-driven largely by the robust adoption of technologies suited for extended care settings.

Key Market Players

  • Cardinal Health, Inc.
  • Essity AB
  • Winner Medical Co., Ltd.
  • Medline Industries, LP
  • DeRoyal Industries, Inc.
  • Smith & Nephew Plc
  • Advanced Medical Solutions Group plc
  • Organogenesis Inc.
  • Convatec Group Plc
  • Kane Biotech Inc.

Report Scope

In this report, the Global Non-Silver Antimicrobial Dressings Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Non-Silver Antimicrobial Dressings Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Non-Silver Antimicrobial Dressings Market.

Available Customizations:

Global Non-Silver Antimicrobial Dressings Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Non-Silver Antimicrobial Dressings Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Region
    • 5.2.2. By Company (2025)
  • 5.3. Market Map

6. North America Non-Silver Antimicrobial Dressings Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Non-Silver Antimicrobial Dressings Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
    • 6.3.2. Canada Non-Silver Antimicrobial Dressings Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
    • 6.3.3. Mexico Non-Silver Antimicrobial Dressings Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast

7. Europe Non-Silver Antimicrobial Dressings Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Non-Silver Antimicrobial Dressings Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
    • 7.3.2. France Non-Silver Antimicrobial Dressings Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
    • 7.3.3. United Kingdom Non-Silver Antimicrobial Dressings Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
    • 7.3.4. Italy Non-Silver Antimicrobial Dressings Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
    • 7.3.5. Spain Non-Silver Antimicrobial Dressings Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast

8. Asia Pacific Non-Silver Antimicrobial Dressings Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Non-Silver Antimicrobial Dressings Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
    • 8.3.2. India Non-Silver Antimicrobial Dressings Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
    • 8.3.3. Japan Non-Silver Antimicrobial Dressings Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
    • 8.3.4. South Korea Non-Silver Antimicrobial Dressings Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
    • 8.3.5. Australia Non-Silver Antimicrobial Dressings Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast

9. Middle East & Africa Non-Silver Antimicrobial Dressings Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Non-Silver Antimicrobial Dressings Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
    • 9.3.2. UAE Non-Silver Antimicrobial Dressings Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
    • 9.3.3. South Africa Non-Silver Antimicrobial Dressings Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast

10. South America Non-Silver Antimicrobial Dressings Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Non-Silver Antimicrobial Dressings Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
    • 10.3.2. Colombia Non-Silver Antimicrobial Dressings Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
    • 10.3.3. Argentina Non-Silver Antimicrobial Dressings Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Non-Silver Antimicrobial Dressings Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Cardinal Health, Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Essity AB
  • 15.3. Winner Medical Co., Ltd.
  • 15.4. Medline Industries, LP
  • 15.5. DeRoyal Industries, Inc.
  • 15.6. Smith & Nephew Plc
  • 15.7. Advanced Medical Solutions Group plc
  • 15.8. Organogenesis Inc.
  • 15.9. Convatec Group Plc
  • 15.10. Kane Biotech Inc.

16. Strategic Recommendations

17. About Us & Disclaimer